155 related articles for article (PubMed ID: 35843174)
1. Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases.
Ceelen W; Sandra L; de Sande LV; Graversen M; Mortensen MB; Vermeulen A; Gasthuys E; Reynders D; Cosyns S; Hoorens A; Willaert W
EBioMedicine; 2022 Aug; 82():104151. PubMed ID: 35843174
[TBL] [Abstract][Full Text] [Related]
2. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
3. Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity.
Lang N; Diciola A; Labidi-Galy I; Ris F; Di Marco M; Mach N; Petignat P; Toso C; Undurraga M; Hubner M
BMJ Open; 2023 Jan; 13(1):e067691. PubMed ID: 36604127
[TBL] [Abstract][Full Text] [Related]
4. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
Takashima A; Shitara K; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Fujii H; Muro K; Esaki T; Choda Y; Takano T; Chin K; Sato A; Goto M; Fukushima N; Hara T; Machida N; Ohta M; Boku N; Shimura M; Morita S; Koizumi W
Gastric Cancer; 2019 Jan; 22(1):155-163. PubMed ID: 29855738
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study.
Murono K; Yokoyama Y; Nozawa H; Sasaki K; Emoto S; Matsuzaki H; Kashiwabara K; Ishigami H; Gohda Y; Yamaguchi H; Kitayama J; Ishihara S
Int J Colorectal Dis; 2023 Jun; 38(1):173. PubMed ID: 37340243
[TBL] [Abstract][Full Text] [Related]
6. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane™) for peritoneal carcinomatosis - a phase I first-in-human study.
Van De Sande L; Graversen M; Hubner M; Pocard M; Reymond M; Vaira M; Cosyns S; Willaert W; Ceelen W
Pleura Peritoneum; 2018 Jun; 3(2):20180112. PubMed ID: 30911657
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
Cristea MC; Frankel P; Synold T; Rivkin S; Lim D; Chung V; Chao J; Wakabayashi M; Paz B; Han E; Lin P; Leong L; Hakim A; Carroll M; Prakash N; Dellinger T; Park M; Morgan RJ
Cancer Chemother Pharmacol; 2019 Mar; 83(3):589-598. PubMed ID: 30623229
[TBL] [Abstract][Full Text] [Related]
10. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer.
Alyami M; Bonnot PE; Mercier F; Laplace N; Villeneuve L; Passot G; Bakrin N; Kepenekian V; Glehen O
Eur J Surg Oncol; 2021 Jan; 47(1):123-127. PubMed ID: 32561204
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
Nakasya A; Hagiwara Y; Ikoma T; Kurioka Y; Matsumoto T; Yamamoto Y; Tsuduki T; Kajiwara T; Moriwaki T; Nishina T; Yamashita N; Hyodo I
Int J Clin Oncol; 2022 Apr; 27(4):684-694. PubMed ID: 35089459
[TBL] [Abstract][Full Text] [Related]
12. Pressurised intraperitoneal aerosolised chemotherapy (PIPAC) for gastric cancer with peritoneal metastases: A systematic review by the PIPAC UK collaborative.
Case A; Prosser S; Peters CJ; Adams R; Gwynne S;
Crit Rev Oncol Hematol; 2022 Dec; 180():103846. PubMed ID: 36257535
[TBL] [Abstract][Full Text] [Related]
13. PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases.
Kim G; Tan HL; Sundar R; Lieske B; Chee CE; Ho J; Shabbir A; Babak MV; Ang WH; Goh BC; Yong WP; Wang L; So JBY
Clin Cancer Res; 2021 Apr; 27(7):1875-1881. PubMed ID: 33148667
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study).
Nakamura M; Ojima T; Katsuda M; Hayata K; Kitadani J; Nakamori M; Yamaue H
Oncology; 2021; 99(1):57-61. PubMed ID: 32877909
[TBL] [Abstract][Full Text] [Related]
15. Safety and preliminary efficacy of electrostatic precipitation during pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable carcinomatosis.
Willaert W; Van de Sande L; Van Daele E; Van De Putte D; Van Nieuwenhove Y; Pattyn P; Ceelen W
Eur J Surg Oncol; 2019 Dec; 45(12):2302-2309. PubMed ID: 31221459
[TBL] [Abstract][Full Text] [Related]
16. No Renal Toxicity After Repeated Treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Unresectable Peritoneal Metastasis.
Larbre V; Alyami M; Mercier F; Vantard N; Bonnefoy I; Opsomer MA; Villeneuve L; Bakrin N; Rioufol C; Glehen O; Kepenekian V
Anticancer Res; 2018 Dec; 38(12):6869-6875. PubMed ID: 30504403
[TBL] [Abstract][Full Text] [Related]
17. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Alyami M; Mercier F; Siebert M; Bonnot PE; Laplace N; Villeneuve L; Passot G; Glehen O; Bakrin N; Kepenekian V
Eur J Surg Oncol; 2021 Jan; 47(1):128-133. PubMed ID: 31253545
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Graversen M; Detlefsen S; Bjerregaard JK; Pfeiffer P; Mortensen MB
Clin Exp Metastasis; 2017 Jun; 34(5):309-314. PubMed ID: 28516306
[TBL] [Abstract][Full Text] [Related]
20. Pressurized Intraperitoneal Aerosol Chemotherapy-Related Clinical Trials in the Treatment of Peritoneal Metastases.
Ukegjini K; Putora PM; Guidi M; Süveg K; Cihoric N; Widmann B; Steffen T
Oncology; 2021; 99(9):601-610. PubMed ID: 34265774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
